Form D · Biotechnology

ExPrimary, Inc.

Rockville, MD · CIK 0001689015

Offering snapshot reported Jan 12, 2022 · SEC filing

Reported sold: $35K
Investors reported: 3
Minimum accepted: $0
First sale: Sep 21, 2017

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$15,000 → $35,000
Reported investors1 → 3

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 12, 2022	Amendment	$35,000	$20,000vs Oct 6, 2017	3	SEC filing
Jan 30, 2020	Amendment	$80,000	$65,000vs Oct 6, 2017	5	SEC filing
May 11, 2018	Initial	$10,000	No comparison	1	SEC filing
Oct 6, 2017	Initial	$15,000	No comparison	1	SEC filing
Nov 2, 2016	Initial	$35,000	No comparison	1	SEC filing

Offering details

Securities: Other
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-296192

Simple Agreement for Future Equity (SAFE)

Source: Form D, filed Jan 12, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Holly Atlee	Executive
Sean Higgins	Director, Executive
Scott Stelick	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

155 Gibbs Street Box 555, Fourth Floor
Rockville, MD, 20850